| 1.58 0.21 (15.33%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.34 | 1-year : | 2.85 |
| Resists | First : | 2.01 | Second : | 2.44 |
| Pivot price | 2.06  |
|||
| Supports | First : | 1.3 | Second : | 1.08 |
| MAs | MA(5) : | 1.84 |
MA(20) : | 2.1 |
| MA(100) : | 1.96  |
MA(250) : | 2.2 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.5 |
D(3) : | 15.4 |
| RSI | RSI(14): 31.4 |
|||
| 52-week | High : | 4.34 | Low : | 0.79 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IKT ] has closed below the lower bollinger band by 0.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 33.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.6 - 1.61 | 1.61 - 1.62 |
| Low: | 1.42 - 1.43 | 1.43 - 1.44 |
| Close: | 1.56 - 1.58 | 1.58 - 1.6 |
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Fri, 19 Apr 2024
Inhibikase Therapeutics progresses in Parkinson's disease trials - Investing.com India
Thu, 18 Apr 2024
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs - GlobeNewswire
Wed, 03 Apr 2024
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension - GlobeNewswire
Thu, 28 Mar 2024
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript - Seeking Alpha
Tue, 05 Mar 2024
HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know - Markets Insider
Thu, 15 Feb 2024
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -12 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 6.57e+006 (%) |
| Held by Institutions | 5.57e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.57 |
| Profit Margin | 0 % |
| Operating Margin | -440 % |
| Return on Assets (ttm) | 356 % |
| Return on Equity (ttm) | 600 % |
| Qtrly Rev. Growth | -118.9 % |
| Gross Profit (p.s.) | 826.08 |
| Sales Per Share | -79.4 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.991e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -0.45 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0 |
| Dividend | 20280 |
| Forward Dividend | 51340 |
| Dividend Yield | 1283540% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|